688520.SH
神州细胞
SSE · Healthcare · Biotechnology · CN
CNY 36.39
−3.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.6B | 2.5B | 1.9B | 1.0B |
| Cost of Revenue | 114.8M | 107.7M | 102.7M | 54.5M | 33.9M |
| Gross Profit | 1.2B | 1.5B | 2.4B | 1.8B | 989.3M |
| Operating Expenses | |||||
| R&D Expense | 831.4M | 837.9M | 911.2M | 1.1B | 886.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 187.4M | 187.2M | 190.2M | 149.7M | 131.5M |
| Selling & Marketing Expense | 825.5M | 843.1M | 694.1M | 436.2M | 264.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.9B | 2.0B | 1.9B | 1.9B | 1.4B |
| Cost and Expenses | 2.1B | 2.1B | 2.0B | 1.9B | 1.4B |
| Operating Income (EBIT) | (617.2M) | (436.3M) | 568.4M | 6.4M | (357.7M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (809.1M) | (563.6M) | 112.3M | (396.8M) | (520.1M) |
| Income Tax Expense | (292.0K) | 2.6M | — | — | — |
| Bottom Line | |||||
| Net Income | (804.3M) | (564.9M) | 112.0M | (396.0M) | (519.0M) |
| Earnings from Cont. Ops | (811.4M) | (566.2M) | 112.3M | (396.8M) | (520.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (804.3M) | (564.9M) | 112.0M | (396.0M) | (519.0M) |
| Per Share | |||||
| Basic EPS | (CN¥1.95) | (CN¥1.32) | CN¥0.24 | (CN¥0.89) | (CN¥1.19) |
| Diluted EPS | (CN¥1.95) | (CN¥1.32) | CN¥0.24 | (CN¥0.89) | (CN¥1.19) |
| Revenue Per Share | CN¥3.18 | CN¥3.65 | CN¥5.39 | CN¥4.24 | CN¥2.35 |
| Shares | |||||
| Basic Shares Outstanding | 428.5M | 427.9M | 466.5M | 445.0M | 436.1M |
| Diluted Shares Outstanding | 428.5M | 427.9M | 466.5M | 445.0M | 436.1M |
| Profitability Metrics | |||||
| EBITDA | — | (266.9M) | 711.8M | 106.6M | (300.5M) |
| D&A | — | 169.5M | 143.4M | 100.3M | 57.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026